To help frame the debate on future EU membership in the context of UK health research, RAND Europe is assessing the benefits and burdens of membership. This research, for the Department of Health, will not only focus on funding, but also look at other aspects such as research environment, network effects, and knowledge spillovers. The project will include a series of scenario-based workshops to explore future impact of EU funding.
To formulate evidence-based conclusions and recommendations for improving the processes of preparing submissions for impact assessment, the higher education funding councils for England, Scotland and Wales have asked RAND Europe to work with a sample of higher education institutions to evaluate the submission process for the impact element of the Research Excellence Framework (REF) 2014.
The European Parliament has asked RAND Europe to provide background information and advice to their members on the role of Smart Cities initiatives and to explain how existing mechanisms perform. The researchers established a working definition of a Smart City and mapped the cities fitting this definition across the Member States. An analysis of the Smart Cities initiatives finds that Smart Cities objectives should be more explicit, well defined and clearly aligned to city development, innovation plans and Europe 2020 to be successful.
The Structural Genomics Consortium (SGC) is a not-for-profit, public-private partnership formed to support drug-discovery through pre-competitive structural biology research. The SGC has commissioned RAND Europe and Canada's Institute on Governance to provide an evaluation of its unique, open-access model, to understand the nature and diversity of its benefits for partnering organisations as well as for the wider research community.
The European and Developing Countries Clinical Trial Partnership asked RAND Europe and Bairds CMC to examine the current research landscape for HIV/AIDS, tuberculosis, malaria and neglected infectious diseases in sub-Saharan Africa. RAND Europe is conducting desk research to identify active researchers and institutions, national strategies and current public funding commitments in these disease areas. Bairds CMC is responsible for in-country, stakeholder interviews.
When treating patients for Hepatitis-C, physicians may be influenced by many factors: their prior experience, the health and social care systems more broadly, or clinical, social and behavioural, or demographic factors. To better understand this decision-making process, GlaxoSmithKline commissioned RAND Europe to investigate the comparative influence and importance of specific factors and combinations of factors and their trade-offs.
The performance of health systems is a key determinant of the inclusiveness of economic growth. Exclusionary, poor quality health care worsens impoverishment, while inclusive health care redistributes the benefits of growth toward the poor and ill. With Kenya and Tanzania as case studies, RAND Europe is exploring the extent to which unexploited potential synergies between industrial development and health systems can strengthen and contribute to faster and more inclusive growth.
The National Institute for Health Research established nine Collaborations for Leadership in Applied Health Research and Care (CLAHRCs) and has commissioned RAND Europe and the Health Economics Research Group at Brunel University to evaluate and learn from the CLAHRCs approach. The goal of the project is to focus on the gap in translating applied research advances into innovations in health and social care, for patient benefit.
What Impact Will Online Energy-Efficiency Ratings Have on the EU’s Lisbon Strategy?
The EU's Lisbon Strategy has a targeted goal of 20% energy efficiency gains by 2020. EU Directive 2010/30/EC has therefore mandated energy efficiency labels on a wider variety of products than was previously the case and further requires this information to be made available online. RAND Europe is assessing the impacts of measures intended to implement this requirement by ensuring that A-G Energy Efficiency rating information is displayed in online sales, rental, and search environments.
Assessing the Evidence Base for Pharmaceutical R&D Models
As research-based drug development is widely viewed as crucial to improving patient health, the pharmaceuticals sector is heavily reliant — and spends a great deal — on research and development. However, there is considerable debate about different R&D models: for example, is it more successful when conducted in a closed, in-house environment or through open networks and partnerships? To help answer this question, Pfizer has asked RAND Europe to investigate the evidence base.
To support decision-making in the research sector, particularly the Department of Health’s research and development directorate, RAND Europe is hosting a research unit on Policy Research in Science and Medicine (PRiSM). Specific PRiSM work streams include supporting the operational decisions of the National Institute for Health Research and researching the 'science of science', or the actual practice of scientific research.
RAND Europe is evaluating the Wellcome Trust's African Institutions Initiative. The initiative funds consortia to build sustainable, independent health research capacity at African universities and research organisations, to promote research collaboration and to train individuals for research careers in Africa. RAND Europe will evaluate the performance of research consortia and the initiative overall and will share learning about African-led and networked research capacity building models.